Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Dimitrios Daoussis1,*, Stamatis-Nick C. Liossis1,*, Athanassios C. Tsamandas2, Christina Kalogeropoulou3, Alexandra Kazantzí3, Chaido Sirinian2, Maria Karampetsou1, Georgios Yiannopoulos1 and Andrew P. Andonopoulos1

See page 201 for the editorial comment on this article (doi:10.1093/rheumatology/kep421)

Abstract

Objective. To assess the efficacy of rituximab (RTX) in SSc.

Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m²)] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Lung involvement was assessed by pulmonary function tests (PFTs) and chest high-resolution CT (HRCT). Skin involvement was assessed both clinically and histologically.

Results. There was a significant increase of forced vital capacity (FVC) in the RTX group compared with baseline (mean ± S.D.: 68.13 ± 19.69 vs 75.63 ± 19.73, at baseline vs 1-year, respectively, \( P = 0.0018 \)). The median percentage of improvement of FVC in the RTX group was 10.25%, whereas that of deterioration in the control group was 5.04% (\( P = 0.002 \)). Similarly, diffusing capacity of carbon monoxide (DLCO) increased significantly in the RTX group compared with baseline (mean ± S.D.: 52.25 ± 20.71 vs 62 ± 23.21, at baseline vs 1-year respectively, \( P = 0.017 \)). The median percentage of improvement of DLCO in the RTX group was 19.46%, whereas that of deterioration in the control group was 7.5% (\( P = 0.023 \)). Skin thickening, assessed with the Modified Rodnan Skin Score (MRSS), improved significantly in the RTX group compared with the baseline score (mean ± S.D.: 13.5 ± 6.84 vs 8.37 ± 6.45 at baseline vs 1-year, respectively, \( P < 0.001 \)).

Conclusion. Our results indicate that RTX may improve lung function in patients with SSc. To confirm our encouraging results we propose that larger scale, multicentre studies with longer evaluation periods are needed.

Key words: Scleroderma, Systemic sclerosis, Rituximab, Interstitial lung disease, Fibrosis, B cells.

Introduction

SSc is a chronic systemic autoimmune disease characterized by vasculopathy and progressive fibrosis. SSc—interstitial lung disease (ILD)—is not uncommon in patients with the diffuse form of the disease and represents the clinical manifestation that dictates prognosis; this manifestation responds poorly to treatment. Therapeutic options for treating SSc-associated ILD are limited and most of the drugs tested so far have shown poor or modest results. Cyclophosphamide (CYC) has shown statistically significant but clinically questionable efficacy in the treatment of SSc-associated ILD, but is associated with immunosuppression underscoring the necessity for novel, more effective and less toxic therapies [1–4]. We and others [5–7] have employed mycophenolate mofetil (MMF) in the treatment of a limited number of patients with SSc-related ILD with encouraging, yet preliminary, results.

1Division of Rheumatology, Department of Internal Medicine, 2Department of Pathology and 3Department of Radiology, Patras University Hospital, University of Patras Medical School, Patras, Greece.

Submitted 23 January 2009; revised version accepted 19 March 2009.

Correspondence to: Dimitrios Daoussis, Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504 Rion, Patras, Greece. E-mail: jmdaoussis@hotmail.com

*Dimitrios Daoussis and Stamatis-Nick C. Liossis contributed equally to this work.

© The Author(s) 2009. Published by Oxford University Press on behalf of The British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
It has been suggested that targeting B cells could be a candidate therapy for SSc, since several lines of evidence point in the direction of B cells having a possible pathogenic role in this debilitating disease [8, 9]. B cells from tight skin mice—an animal model of SSc—exhibit chronic hyperactivity and exaggerated calcium responses after B-cell receptor (BCR) cross-linking. B cells from this animal model show augmented CD19 (an important positive BCR response regulator) signalling caused by impaired function of CD22, a negative BCR response regulator [10]. Likewise, B cells from patients with SSc overexpress CD19, compared with B cells from healthy subjects and disease control patients, and are chronically activated [11]. Furthermore, studies revealed that B-cell genes were specifically transcribed in SSc skin [12] and that B-cell infiltration was a prominent feature of SSc-associated ILD [13].

Rituximab (RTX) is a chimeric mAb against human CD20 that depletes peripheral B cells. It has been successfully introduced in the treatment of systemic rheumatic diseases and exhibits an acceptable safety profile. In animal models of SSc, administration of anti-CD20 mAb to newborn tight skin mice led to significant suppression of skin fibrosis [14]. On the other hand, there are encouraging data from the literature regarding the use of RTX in chronic graft vs host disease (GVHD) [15–18]. GVHD is a late complication of heterologous haematopoietic stem-cell transplantation and exhibits several similarities to SSc, such as scleroderma-like skin manifestations and circulating autoantibodies. Furthermore, chronic GVHD has been considered by some as a systemic autoimmune disease [19–22]. The observed microchimerism in a significant percentage of patients with SSc may further suggest pathogenetic similarities between the two entities, justifying similar therapeutic trials [23, 24]. Recently, two uncontrolled studies have explored the potential clinical efficacy of RTX in SSc. In the first one, skin fibrosis as assessed clinically and histologically improved significantly in the RTX-treated patients [25]. In the second one, even though no overt clinical benefit was observed, skin biopsies from RTX-treated patients exhibited a significant reduction in the myofibroblast score and the patients remained clinically stable throughout the study period [26]. There are also two additional reports (in abstract form) showing improvement of skin fibrosis [27, 28] and a case report of improvement of SSc-associated ILD [29]. The preliminary encouraging results from the use of RTX in animal models of SSc and in humans with chronic GVHD and SSc has led us to investigate more thoroughly the potential efficacy of RTX in patients with SSc in an open-label, proof-of-principle, randomized, controlled study. We report herein that RTX treatment of patients with SSc and SSc-associated ILD led to improvement of lung function and was well tolerated.

Patients and methods

Patients

We enrolled 14 patients with a diagnosis of SSc, fulfilling the preliminary ACR criteria for the classification of the disease (30). Baseline demographic and clinical characteristics of the patients are presented in Table 1. All patients underwent a complete physical examination and a detailed review of their medical records prior to study enrolment. Other variables were also evaluated (full blood count, biochemistry profile, autoantibody profiles, urinalysis, ECG and cardiac ultrasound).

Inclusion criteria were: (i) the detection of anti-Scl-70 autoantibodies in their sera; (ii) the presence of SSc-associated ILD as indicated by findings in either high-resolution CT (HRCT) of the chest or pulmonary function tests (PFTs) or both; and (iii) the absence of any changes in medications and/or dosage of treatment administered during the last 12 months before enrolment. All patients belonged to the diffuse variety of the disease as documented by the clinical presentation of skin involvement at the time of the study and/or its course over time since diagnosis. Moreover, all patients were anti-Scl-70 positive and had significant ILD, a feature of diffuse SSc. No changes in medication were allowed during the study.

A local (Patras University Hospital, Patras, Greece) ethics committee approved the study (which fulfilled the Declaration of Helsinki requirements) and a written informed consent was obtained from all participating individuals.

| Table 1 | Baseline characteristics of RTX and control group |
|-------------|-----------------|-----------------|---|
| **RTX** | **Control** | **P-value** |
| Age, median (range), years | 53 (41–66.5) | 56 (47.7–68.5) | NS |
| Disease duration, mean ± s.d., years | 6.87 ± 4.88 | 8.33 ± 5.6 | NS |
| HAQ-DI, median (range) | 0.687 (0.28–1.25) | 0.312 (0.09–0.90) | NS |
| MRSS, mean ± s.d. | 13.5 ± 6.84 | 11.5 ± 2.16 | NS |
| FVC, mean ± s.d. | 68.13 ± 19.69 | 86 ± 19.57 | NS |
| DLCO, mean ± s.d. | 52.25 ± 20.71 | 65.33 ± 21.43 | NS |
| HRCT score, mean ± s.d. | 13.1 ± 4.5 | 16.4 ± 6.4 | NS |

FVC and DLCO are expressed as a percentage of normal predicted values based on age, sex and height. HAQ-DI: HAQ-disability index; MRSS: Modified Rodnan Skin Score; NS: non-significant.
Randomization and treatment

Patients born on an even-numbered date \( n = 8 \) were assigned to the RTX group and those born on an odd-numbered date \( n = 6 \) to the control group. Patients in the RTX group received four weekly pulses of RTX (375 mg/m\(^2\)) at baseline and at 6 months on top of the already administered treatment. Patients in the control group continued their previously administered treatment unchanged (details in Table 2). Four patients in the RTX group (Patients 2, 4, 5 and 6) and two in the control group (Patients 11 and 14) were on MMF therapy during study enrolment and remained so throughout the study. They have been on that therapy for at least 4 years prior to study enrolment (apart from Patient 14 who was on MMF therapy for 2 years prior to enrolment). Three patients in the RTX group (Patients 2, 3 and 4) and one in the control group (Patient 10) had received CYC in the past but were off that therapy for at least 3 years prior to study enrolment. There were no significant differences between the two patient groups as shown in Table 2.

PFT

Standard PFTs were performed, at baseline, at 24 weeks and at 1 year in all patients, including assessments of forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), total lung capacity and diffusing capacity of carbon monoxide (DL\(_{\text{CO}}\)) corrected for haemoglobin concentration. PFT parameters are expressed as a percentage of normal predicted values based on age, sex and height. All tests were performed at the same laboratory, at our institution (Patras University Hospital).

Chest HRCT

All patients had an HRCT performed at baseline and at 24 weeks using a 16 multi-detector GE CT Scan (General Electric, Waukesha WI, USA) with slice thickness of 0.625 mm. Imaging findings were interpreted separately by two experienced radiologists (C.K. and A.K.) in a blinded fashion. Acquisition parameters of tube voltage, tube current and slice thickness were 140 kilovolt potential (kVp), 300 mA and 0.625 mm, respectively. In order to obtain contiguous images of lung abnormalities, a second low-dose scanning (120 kV, 200 mA) was performed with slice thickness of 1.25 mm, covering the whole thorax. This protocol permitted data reconstruction and evaluation of images in coronal and sagittal levels using multiplanar reformatting algorithm. The severity and extent of lung involvement was assessed according to the scoring system proposed by Warrick et al. [31] as follows: one point was assigned to ground glass appearance, two points to irregular pleural margins, three to septal/subpleural lines, four to honeycombing and five to subpleural cysts. The sum of points results in the severity score (0–15 points). Extent score was calculated giving 1 point when involvement of one to three lung segments was present, 2 points for four to nine segments and 3 points to more than 10 segments (0–15 points). Total score was obtained by adding the two above scores (0–30 points).

Clinical assessment of skin thickening

The MRSS was used for clinical assessment of skin thickening at baseline and at 1 year, by an experienced assessor in a blinded fashion [32, 33].

Skin histology

Histological assessment of skin fibrosis was made by skin biopsies performed at baseline and at 24 weeks of evaluation (a 5-mm punch biopsy of lesional skin). Skin biopsies were performed in six patients of the RTX group and three patients of the control group (including those receiving CYC) and were performed prior to RTX administration. Biopsies were taken from lesional skin

### Table 2: Demographics, clinical and laboratory parameters of the cohort

| Patient no./sex/age | Disease duration, years | FVC at baseline | FVC at 1 year | DL\(_{\text{CO}}\) at baseline | DL\(_{\text{CO}}\) at 1 year | MRSS at baseline | MRSS at 1 year | Histological improvement | Skin B-cell depletion | Concurrent medications |
|---------------------|------------------------|-----------------|--------------|----------------------------|--------------------------|-----------------|------------------|------------------------|---------------------|------------------------|
| RTX                 |                        |                 |              |                           |                          |                 |                  |                        |                     |                        |
| 1/F/47              | 6                      | 85              | 88           | 67                        | 78                       | 14              | 10               | No                     | No                  | Pred, Bos             |
| 2/M/72              | 5                      | 55              | 62           | 40                        | 49                       | 8               | 2                | Yes                    | Yes                 | Pred, MMF             |
| 3/F/56              | 6                      | 70              | 75           | 33                        | 38                       | 10              | 4                | Yes                    | No                  | Pred, Bos             |
| 4/M/39              | 13                     | 30              | 35           | 14                        | 27                       | 29              | 21               | Yes                    | Yes                 | Pred, Bos, MMF        |
| 5/F/33              | 15                     | 85              | 90           | 71                        | 96                       | 16              | 14               | No                     | No                  | Pred, MMF             |
| 6/F/56              | 7                      | 90              | 97           | 67                        | 67                       | 12              | 4                | Yes                    | Yes                 | MMF                   |
| 7/F/70              | 1                      | 68              | 84           | 64                        | 81                       | 11              | 8                | NA                     | NA                  | –                      |
| 8/F/50              | 2                      | 62              | 74           | 62                        | 60                       | 8               | 4                | NA                     | NA                  | Pred                   |
| Control             |                        |                 |              |                           |                          |                 |                  |                        |                     |                        |
| 9/F/80              | 9                      | 72              | 75           | 61                        | 59                       | 13              | 14               | No                     | No                  | Pred, CYC             |
| 10/F/73             | 15                     | 57              | 52           | 26                        | 16                       | 12              | 10               | No                     | No                  | Pred                   |
| 11/F/48             | 5                      | 114             | 110          | 84                        | 79                       | 14              | 9                | NA                     | NA                  | Pred, Bos, MMF        |
| 12/F/47             | 4                      | 91              | 85           | 66                        | 60                       | 12              | 9                | No                     | No                  | Pred, CYC             |
| 13/F/67             | 5                      | 88              | 70           | 84                        | 65                       | 8               | 4                | NA                     | NA                  | Pred                   |
| 14/F/52             | 2                      | 94              | 98           | 71                        | 82                       | 10              | 12               | NA                     | NA                  | Pred, MMF             |

Pred: low-dose prednisone; Bos: Bosentan; NA: not applicable.
and date) fashion.

**Evaluation of skin biopsies.** All skin biopsies were fixed in 10% neutral buffered formalin and embedded in paraffin. Four micrometre-thick paraffin sections were obtained and stained with haematoxylin and eosin, and Masson’s trichrome (fibrosis evaluation). All trichrome stains of biopsies were performed at the same time, using the same staining set (04-011802-Masson trichrome, Goldner-Bioptica, Milan, Italy) in order to have comparable results.

**Fibrosis quantification.** To quantify collagen accumulation in the dermis, we employed the Image J software (freely downloadable and developed by Wayne Rasband at the Research Services Branch of the NIH) according to the method described previously [34]. A similarly and simultaneously stained skin biopsy from skin keloid was analysed as well, representing a positive control for collagen deposition. Collagen deposition was examined separately for the papillary and the reticular dermis.

**Results**

**Efficacy end points**

Primary end points included evaluations of (i) changes in pulmonary function as assessed by PFT and (ii) clinical assessment of skin involvement by the MRSS. Secondary outcome measures included changes in (i) skin histology including collagen deposition and lymphocytic infiltration, (ii) HRCT scores, (iii) serum levels of soluble markers and (iv) overall functional impairment.

**Statistical analysis**

Statistical analysis was performed using the SPSS software (SPSS Inc., Chicago, IL, USA), version 14. Data are presented as mean ± s.d., median (upper and lower quartile values) or percentages, as appropriate. The paired Student’s t-test, Wilcoxon matched pairs test, Mann–Whitney test and Fisher’s exact test were used where indicated. Values of $P<0.05$ were considered as statistically significant.

**Effects of RTX treatment on SSC-associated ILD**

PFTs and HRCT were used to assess the potential effect of RTX administration on SSC-associated ILD.

**PFTs improve following RTX treatment.** At the 1-year evaluation, there was a significant increase of FVC in the RTX group compared with baseline (mean±s.d.: 68.13±19.69 vs 75.63±19.73, at baseline vs 1 year, respectively, $P=0.0018$), whereas no change was noticed in the control group (mean±s.d.: 86±19.57 vs 81.67±20.69, at baseline vs 1 year, respectively, $P=0.23$), as shown in Fig. 1A and B. The median (upper and lower quartile values) percentage of improvement of FVC in the RTX group was 10.25% (6.19–18.65), whereas in the control group FVC deteriorated (median percentage of deterioration (upper and lower quartile values) 5.04% (4.11–11.6)). Direct comparison of FVC changes recorded at 1 year revealed that the RTX-treated group improved significantly ($P=0.002$) compared with the standard treatment (control) group.

There was a significant increase of DLCO in the RTX group compared with baseline (mean±s.d.: 52.25±20.71 vs 62±23.21, at baseline vs 1 year, respectively, $P=0.017$), whereas no changes were noticed in the control group (mean±s.d.: 65.33±21.43 vs 60.17±23.69, at baseline vs 1 year, respectively, $P=0.25$), as shown in Fig. 1C and D. The median (upper and lower quartile values) percentage of improvement of DLCO in the RTX group was 19.46% (3.7–30.8), whereas in the control group the median percentage of deterioration (upper and lower quartile values) was 7.5% (1.4–26.57) ($P=0.023$).

The improvement of lung function tests in the RTX-treated patients was already evident in the 24-week evaluation (mean±s.d.: 71.5±21.3 and 55.2±25.1 for FVC and DLCO, respectively).

**Effects of RTX treatment on HRCT.** HRCT scores were identical at baseline and at 24 weeks in all patients in the forearm; the second biopsy was taken from lesional skin adjacent (always <2 cm) to the site of the baseline biopsy (supplementary Fig. 1, available as supplementary data at Rheumatology Online).
the RTX group (mean ± s.d.: 13.1 ± 4.5). In the control group, there was a modest increase in the HRCT score that was not statistically significant (mean ± s.d.: 16.4 ± 6.4 vs 16.8 ± 6.5, at baseline vs 24 weeks, respectively, $P = 0.170$).

Effects of RTX treatment on skin disease in patients with SSc

To evaluate any potential effect of RTX on skin involvement we performed standard clinical assessment and skin biopsy analysis.

Effects of RTX treatment on skin thickening, as clinically assessed. Skin thickening, assessed with the MRSS, was similar in the two treatment groups at baseline (Table 1, $P = 0.50$). However, at the 1-year evaluation, there was a significant decrease of MRSS in the RTX group compared with the baseline score (mean ± s.d.: 13.5 ± 6.84 vs 8.37 ± 6.45 at baseline vs 1 year, respectively, $P = 0.0003$). On the contrary, no significant change in skin scores was noticed in the control group at 1 year when compared with the baseline MRSS (mean ± s.d.: 11.50 ± 2.16 vs 9.66 ± 3.38 at baseline vs 1 year, respectively, $P = 0.16$). The median (upper and lower quartile values) percentage of improvement in the RTX-treated group was 39.25% (27.33–64.95) compared with 20.80% (10.78–39.28) in the control group. Statistical analysis revealed that despite differences, the values were not statistically significant ($P = 0.06$).

Effects of RTX treatment on collagen deposition. In the RTX-treated group, there was a significant reduction of collagen deposition in the papillary dermis at 24 weeks compared with baseline (mean ± s.d.: 51.75 ± 19.78 vs 31.68 ± 14.02 at Week 0 vs Week 24, respectively, $P = 0.030$). The control group showed no change in collagen deposition in the papillary dermis at 24 weeks compared with baseline values (mean ± s.d.: 46.53 ± 22.43 vs 46.27 ± 10.49 at baseline vs Week 24, respectively, $P = 0.980$). The median (upper and lower quartile values) percentage of improvement of skin fibrosis in the RTX group was 38.33% (6.86–59.9), whereas in the control group skin fibrosis worsened (median percentage of worsening of skin fibrosis was 5.23%). Histological improvement was evident in four patients (Patients 2, 3, 4 and 6) of the RTX group and coincided with clinical improvement in these patients (Table 2). Differences were not statistically significant ($P = 0.09$). Representative skin histology is shown in Figs 2 and 3.

When collagen deposition in the reticular dermis was evaluated comparatively at baseline and at Week 24, there were no differences either in the RTX (mean ± s.d.: 76.57 ± 16.04 vs 73.07 ± 9.86 at Week 0 vs Week 24, respectively, $P = 0.758$) or in the control group (mean ± s.d.: 50.97 ± 28.88 vs 57.03 ± 22.63 at Week 0 vs Week 24, respectively, $P = 0.498$) of patients with SSc. Exceptionally, a striking improvement was observed in Patient 2 (RTX group), who displayed a significant reduction of skin fibrosis not only in the papillary but in the reticular dermis as well, and had clinically an almost
complete resolution of sclerodermatous skin lesions (Fig. 2C and D).

**Effects of RTX on skin infiltrating B cells.** The presence of T and B cells was assessed by immunohistochemistry in all biopsies. Representation of T cells was substantially limited in all patients; these were predominantly CD8⁺ T cells and no differences were observed at 24 weeks, compared with baseline (data not shown). The number of B cells was relatively low as well, but they were more abundant than T cells. RTX administration significantly reduced the number of B cells in three patients (Patients 2, 4 and 6) but had no effect on the remaining three patients of the RTX group (Patients 1, 3 and 5).

Patients exhibiting B-cell depletion in the skin following RTX administration were the ones with the higher numbers of B cells at baseline. All three patients with skin B-cell depletion improved histologically. However, among the three non-B-cell depletors, there was a single patient who improved histologically (Patient 3). In the control group no difference was recorded in B cell numbers at 24 weeks compared with baseline. All data and representative skin immunohistochemistry are shown in Fig. 4.

**Overall functional impairment**

There was a significant improvement in HAQ scores at 1 year compared with baseline in the RTX group.
Fig. 4 (A) Effects of RTX on skin infiltrating B cells. Numbers of infiltrating B cells in the dermis (y-axis) at baseline and at 24 weeks. The mean ± s.d. of infiltrating B cells was 5.41 ± 3.73 vs 2.70 ± 1.47 at week 0 vs week 24, respectively, P = 0.110 for the RTX group and 5.69 ± 2.16 vs 5.32 ± 1.36 at week 0 vs week 24, respectively, P = 0.54 for the control group. The arrows indicate patients with histological evidence of improvement of skin fibrosis. Apart from Patient 3, in all other patients improvement of skin histology is associated with RTX-induced decreases in the numbers of skin-infiltrating B cells. (B) Elimination of skin-infiltrating B cells of Patient 2 before (A) and following RTX (B) at 24 weeks.

Markers of endothelium activation/injury and ET-1

To examine any potential effects of RTX administration on endothelium, which is a key player in SSc pathogenesis, we measured serum levels of three markers of endothelium activation/injury [E-selectin, vascular cell adhesion molecule (VCAM) and inter-cellular adhesion molecule-1 (ICAM-1)] and ET-1. There was a trend towards a decrease in all three endothelium activation/injury markers and ET-1 serum levels in the RTX group at 24 weeks, compared with baseline, which did not reach statistical significance. It was worth noticing though that the patients with histological improvement in skin biopsy (Patients 2, 3, 4 and 6) were the ones who displayed a decrease in serum levels of at least three of the four markers studied. In the control group, even though no statistically significant changes were observed, VCAM and ET-1 levels showed an upward trend at 24 weeks compared with baseline (data not shown).

Adverse events

Patient 4 (RTX group) suffered a respiratory tract infection 3 months after the second cycle of RTX. The patient was hospitalized for 3 days, treated with intravenous antibiotics and oxygen supplementation and recovered fully in a few days.

Discussion

This is the first randomized controlled study in the literature to evaluate the efficacy of RTX in patients with SSc. In this study, we report an improvement in lung function with an increase in FVC and DLCO at 1 year, following two cycles (composed of four weekly doses each) of RTX in patients with SSc compared with the control group. Perhaps more importantly, none of the RTX-treated patients exhibited worsening of either FVC or DLCO, whereas five out of six patients had declining FVC and DLCO values at 1 year in the control group. These results indicate that RTX may favourably affect lung function parameters in patients with SSc. We should note, however, that patients in the control group tended to have more early disease and better lung function parameters (although not statistically different from the RTX group) making them more likely to deteriorate over the time of the study. Radiological assessment of ILD by HRCT revealed no changes in the RTX group, whereas there was a minor deterioration of two patients in the control group. It is of importance to note that none of the patients in the RTX group displayed worsening of lung fibrosis assessed by HRCT. Therefore, our HRCT studies support the idea that RTX treatment may stabilize pulmonary lesions apparent on imaging in diffuse SSc. The contrast between the RTX-induced improvement of lung function and the lack of improvement in the imaging studies may stem from using the Warrick scoring system, which is a rather crude method of assessment, or because the time interval of evaluation (24 weeks) was too short. Alternatively, most of the lesions apparent on HRCT may represent established fibrosis and not active lesions even though the effects of RTX are incompletely understood on both these parameters.

Although improvement in skin thickening, assessed by MRSS, has been reported in some studies evaluating the efficacy of different therapeutic agents in SSc, histological confirmation of improvement has only been documented following stem-cell transplantation [39]. Improvement of skin fibrosis also occurs in the long term during the
physical course of the disease. In this study, improvement of skin thickening, as assessed clinically, was evident in the isolated analysis in the RTX group but head-to-head comparisons with the control group revealed that differences strongly tended to reach statistical significance, but did not reach it. This may be due to the small number of participants and the short time interval (24 weeks) between biopsies. Nevertheless, the improvement depicted in our figures from skin histology may suggest a potentially modifying role of RTX in the pathological process of skin fibrosis in SSc.

Two recent uncontrolled studies have explored the potential clinical efficacy of a single cycle of RTX in SSc. In the study by Smith et al. [25], clinical and histological improvement of skin fibrosis was observed at 24 weeks following RTX treatment and in the study by Lafyatis et al. [26], a significant reduction of the myofibroblast score in skin biopsies of RTX-treated patients was reported. These data are in agreement with ours and suggest that RTX may favourably affect skin fibrosis in SSc. Lung function tests at 24 weeks were stable in both the previously mentioned studies. We should note, however, that only 7 out of 15 patients in the study by Lafyatis et al. and 5 out of 8 patients in the study by Smith et al. had evidence of mild ILD (since patients with significant ILD were excluded), whereas in our study the presence of ILD was one of the inclusion criteria (and most patients had significant ILD). Furthermore, our study is the first in the literature to report lung function parameters at 1 year following RTX administration and the first to report the effects of two consecutive cycles of RTX on lung function and skin thickening in SSc.

Although RTX has been successfully introduced lately in the treatment of various autoimmune diseases, its exact mechanism of action is not completely understood. Pathogenesis of SSc is largely unknown but the results of the present study indicate that B cells may play a role and RTX may have a favourable effect on the disease process. RTX targets B cells that are present in skin biopsies of patients with scleroderma [40] and are the source of autoantibodies, some of which may contribute to pathogenesis [41]. In addition, it has become clear that apart from peripheral B-cell depletion, RTX indirectly affects other immune cells such as T cells [42, 43], which have been implicated in SSc pathogenesis as well [44, 45]. In our study, improvement of skin fibrosis was more commonly encountered in patients with evidence of B-cell depletion in the skin, indirectly supporting a potential role of B cells in SSc. Although our data are preliminary, we may propose that the number of infiltrating B cells in the dermis, as assessed by skin biopsy, could serve as a marker of response to RTX therapy in patients with SSc.

Our study has several potential limitations. The first one is the small number of patients recruited, which does not provide the study with sufficient statistical power to prove efficacy. Indeed, this is a proof-of-principle study that was performed in order to obtain preliminary data regarding the effect of RTX on a limited number of patients with SSc. We designed the study as an open label randomized controlled one, so that we can compare the results of the RTX-treated patients with a similarly affected control group of patients receiving standard treatment and care. An additional limitation is that most patients had long-standing disease and had received various forms of immunosuppressive treatment in the past. The patients enrolled in our study are heterogeneous in terms of disease duration, severity and previous treatments. Ideally, one should have recruited patients with early disease and with no previous exposure to other forms of immunosuppressive treatment, but this approach might be hampered by disease rarity. Yet another limitation is that patients in both the RTX and the control group received several concurrent immune-based therapies and even though they were on the same treatment for a significant amount of time prior to enrolment, one cannot rule out the possibility that these therapies contributed to the outcomes reported in this study. Furthermore, improvement of skin fibrosis may associate with the natural course of the disease; nevertheless, improvement of skin fibrosis was seen only in our RTX-treated group and not in the control group.

We report herein the results of a controlled study evaluating the efficacy of RTX in patients with SSc and SSc-associated ILD. Our data, although preliminary and on a small cohort, indicate a possible disease-modifying role of RTX in SSc, particularly in SSc-associated lung disease. However, in SSc treatment several therapeutic agents have shown some efficacy in small-scale studies but failed to do so in larger scale studies. Taking into consideration the limitations of the present study, definite conclusions should not be drawn. Nevertheless, our data could serve as a good starting point for the design of larger scale, multicentre studies with longer evaluation periods and especially in earlier stages of the disease.

**Rheumatology key messages**

- Several lines of evidence indicate a potential role of B cells in the pathogenesis of scleroderma.
- RTX may improve lung function in patients with SSc.
- Large-scale, multicentre studies are needed to evaluate the potential efficacy of RTX in scleroderma.

**Acknowledgements**

D.D., S.N.C.L and A.P.A had full access to all data and were responsible for data analysis and interpretation of the results. Study design and manuscript preparation was by D.D., S.N.C.L and A.P.A. Acquisition of data was by D.D., S.N.C.L, M.K. and G.Y. Assessment of HRCT was by C.K. and A.K. Pathological evaluation of skin biopsies was by A.C.T. Immunohistochemistry was by C.S. Statistical analysis was by D.D.

**Funding:** This work was supported by the Hellenic Rheumatology Society (a non-profitable organization that
did not interfere in any stage of this study). Funding to pay the Open Access publication charges for this article was provided by Roche Hellas.

Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data
Supplementary data are available at Rheumatology Online.

References

1. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
2. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026–34.
3. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962–70.
4. Yiannopoulos G, Pastromas V, Antonopoulos I et al. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007;27:357–61.
5. Nihtyanova SI, Brough GM, Black CM, Denton CP. Cyclophosphamide motefil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005–8.
6. Nihyanoa SI, Brough GM, Black CM, Denton CP. Mycophenolate motefil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology 2007;46:442–5.
7. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE. Mycophenolate motefil for interstitial lung disease in scleroderma. Rheumatology 2006;45:1572.
8. Fujiimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746–51.
9. Sato S, Fujiimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004;41:1123–33.
10. Asano N, Fujiimoto M, Yazawa N et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004;165:641–50.
11. Sato S, Fujiimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918–27.
12. Whitfield ML, Finlay DR, Murray JL et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319–24.
13. Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167–8.
14. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954–66.
15. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweet JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104:2603–6.
16. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host disease. Leuk Lymphoma 2007;48:623–4.
17. Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756–62.
18. Okamoto M, Okano A, Akamatsu S et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172–3.
19. Tivel E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005;105:4885–91.
20. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007;20:349–60.
21. Perruche S, Marandin A, Kleinclauss F et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation 2006;81:573–82.
22. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006;66:1041–57.
23. Nelson JL, Furst DE, Maloney S et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998;351:559–62.
24. Murata H, Nakauchi H, Sumida T. Microchimerism in Japanese women patients with systemic sclerosis. Lancet 1999;354:220.
25. Smith VP, Van Praet JT, Vandooren BR et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. Advance Access published December 22, 2008, doi: 10.1136/ard.2008.095463v1.
26. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578–83.
27. Bosello S, De Santis M, Lama G et al. Clinical improvement in systemic sclerosis patients treated with anti-CD20. Arthritis Rheum Suppl 2007;56:494.
28. Lombardi S, Quartuccio L, Franzolini N et al. Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Sup 2008;58:S82–3.
29. McGonnagle D, Tan AL, Madden J et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008;47:552–3.
30 Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.

31 Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18:1520–8.

32 Valentini G, D’Angelo S, Della RA, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:966–9.

33 Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966–9.

34 Rangan GK, Tesch GH. Quantification of renal pathology by image analysis. Nephrology 2007;12:553–8.

35 Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP, Tsaumandas AC. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001;9:329–34.

36 Khanna D, Furst DE, Clements PJ et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–40.

37 Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27–31.

38 Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337–42.

39 Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388–96.

40 Wollheim FA. Is rituximab a potential new therapy in systemic sclerosis? New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 2004;10:155.

41 Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667–76.

42 Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501–13.

43 Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion in patients with lupus nephritis. Clin Immunol 2007;123:66–73.

44 Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679–85.

45 Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50:1721–33.